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GENERAL CONSIDERATIONS
Guidelines for athletic participation are needed to reduce
the risk for arrhythmia-related morbidity or mortality.
However, it is often difficult to establish the importance of
a cardiac rhythm disturbance in assessing an athlete’s
eligibility for competition. Few data exist that have been
obtained prospectively from well-designed, scientifically
acceptable studies to determine whether a particular rhythm
disturbance predisposes an athlete to sudden death or to
symptoms, such as syncope or presyncope, that could
precipitate severe injury. Sudden unexpected cardiac death
in the young is rare, estimated at less than 1% of that
observed in adults. Nonetheless, a significant proportion of
these deaths occur in relation to exercise (1). The deaths of
several prominent athletes have focused attention on ath-
letes with known arrhythmias.
Arrhythmias commonly are evanescent, often disappear-
ing unpredictably for long periods of time, in some cases
years. If they recur when the athlete is not exercising, the
arrhythmia may not be noted or may not produce significant
symptoms. The same arrhythmia may minimally affect a
competitive golfer but severely incapacitate other athletes,
such as cross-country skiers, performing at peak physical
effort. The athlete may not develop the arrhythmia during
each sporting event. Although the reasons for this are not
known, factors related to the autonomic nervous system
probably play a very important role in determining whether
an arrhythmia occurs and its rate and effect on hemody-
namic responses and symptoms. Autonomic “tone” probably
varies greatly and perhaps unpredictably between and within
athletic events and from one athlete to another. Mental
stress during competition can produce important electro-
physiologic and hemodynamic changes that are probably
mediated through the autonomic nervous system.
It is important to understand the range of normal heart
rate and rhythm for the trained athlete. Heart rates of 25
beats/min and sinus pauses lasting greater than 2 s may be
found on 24-h Holter ambulatory electrocardiographic
(ECG) recordings. Type I second-degree atrioventricular
(AV) block and single uniform premature ventricular com-
plexes each may occur in approximately 40% of athletes.
Complex ventricular arrhythmias (multiform premature
ventricular complexes, couplets, nonsustained ventricular
tachycardia) are less common (2,3).
Many of our conclusions result from data obtained in
non-athletes, from general perceptions, or experience and
from a heavy input of “what seems reasonable.” Decision-
making based on this type of logic is often faulty but is the
best available. Recommendations and guidance need to be
balanced between an effort to avoid restricting activity
unduly and the hope of reducing the risk of death and injury
due to a rhythm disturbance.
Despite the lack of complete information, some firm
conclusions can be reached. Certain arrhythmias, such as
ventricular tachyarrhythmias, create symptoms and are dan-
gerous in and of themselves regardless of the clinical
situation in which they occur (4). These arrhythmias gen-
erally are characterized by very rapid or very slow heart rates
that significantly compromise cardiac output, coronary or
cerebral blood flow, or maintenance of blood pressure. Such
arrhythmias may include atrial flutter or atrial fibrillation
with uncontrolled ventricular rates of 200 to 300 beats/min,
usually (but not exclusively) in athletes with Wolff-
Parkinson-White (WPW) syndrome, rapid sustained ven-
tricular tachycardias, and AV block, or sinus node disease
with very slow ventricular rates. Certain persistent arrhyth-
mias, such as chronic tachycardias, can worsen cardiac
function by a process called “remodeling” (5). Other ar-
rhythmias, such as AV nodal re-entrant tachycardia, gener-
ally well-tolerated in most people, may not produce impor-
tant symptoms at rest but only during exercise in athletes
with structural heart disease due, in part, to an increase in
the tachycardia rate. Arrhythmias that might otherwise be
innocuous and no more than a nuisance might, under
conditions of participation in certain sports involving body
contact or high speed, place the athlete at risk of injury or
death because of transient impaired mental function causing
loss of physical control. For example, it is possible that an
athlete with supraventricular tachycardia participating in
potentially dangerous sports, such as diving, downhill ski-
ing, or auto racing, may be at greater risk because of
dizziness, near syncope (a feeling of impending loss of
consciousness), or syncope than if he or she were playing
basketball or baseball.
The search for significant structural heart disease is an
important element in evaluating athletes with arrhythmias
prior to sports participation. Some athletes with coronary
artery disease (CAD), hypertrophic cardiomyopathy, ar-
rhythmogenic right ventricular cardiomyopathy (ARVC),
aortic stenosis, some inherited cardiac channelopathies like
congenital long QT syndrome (LQTS) (6), and other forms
of congenital heart disease, including repaired congenital
heart disease, are probably at greater risk for cardiac arrest
and sudden death during and, perhaps, just after exercise.
1354 Zipes et al. JACC Vol. 45, No. 8, 2005
Task Force 7: Arrhythmias April 19, 2005:1354–63
This is probably true whether or not arrhythmias have been
recognized previously. In general, athletes with symptoms
possibly related to cardiac arrhythmia, such as exertional- or
auditory-triggered syncope, near syncope, and palpitations,
should be carefully evaluated (see Task Force 2: Congenital
Heart Disease) before being permitted to participate in
competitive sports. A consideration of cardiac hemody-
namic status is critical because right or left ventricular
dysfunction is an additional important predictor of arrhyth-
mic death. The presence of a significant rhythm distur-
bance, such as a rapid supraventricular or ventricular tachy-
arrhythmia in athletes with abnormal cardiac hemodynamic
status (from any cause), itself is definitely incompatible with
participation in all competitive sports. However, it is im-
portant to emphasize that some disease states, such as a
myocarditis, can produce arrhythmias that can be self-
limited, with subsequent full recovery.
In general, all athletes with significant cardiac arrhyth-
mias being considered for athletic activity should have a
careful cardiac examination, a 12-lead ECG, echocardio-
gram, exercise test, and, in some, a long-term 24-h Holter
ambulatory ECG recording, if possible during the specific
type of exercise being considered. Arrhythmias, as discussed
in the various Task Force documents, are usually identified
by exercise testing or some form of long-term monitoring
(including ambulatory Holter and event recording). Ar-
rhythmias precipitated during the specific type of exercise
being considered can be important because a conventional
exercise test may not replicate the specific clinical situation
produced by actively participating in the sport. In this
regard, exercise tests may need to be adapted specifically for
the athlete; that is, to begin exercise at peak energy
expenditure, as a sprinter in a race might, rather than with
the slow increase in workload commonly used in testing
athletes with CAD. Resuscitation equipment and trained
personnel may be needed on a standby basis.
All athletes with an arrhythmia who are permitted to
engage in athletics should be re-evaluated at 6 to 12 month
intervals after they are trained, to determine whether the
conditioning process affected the arrhythmia. It should also
be stressed that athletes with arrhythmias controlled by
antiarrhythmic drugs may stop taking these drugs for a
variety of reason and, therefore, compliance with recom-
mended therapy, as well as evaluation for recurrence of
symptoms, must be established periodically. Abuse with
drugs like cocaine or ephedra can precipitate life-
threatening arrhythmias, and such considerations are an
important part of the evaluation. Of note, the use of certain
cardioactive drugs, such as beta-adrenergic blocking agents,
is banned in some competitive sports (see the Introduction).
In addition, it is important to realize that the cat-
echolamines released during exercise may counteract the
salutary effects of some antiarrhythmic agents. For some
arrhythmias, an ablation approach, usually with a catheter
and usually with radiofrequency energy, to eliminate the
arrhythmia may be preferable to drug treatment. Other
ablation energies, such as cryoablation, or other approaches
such as surgery, can be used as indicated. After successful
ablation of the arrhythmia, a return to athletics can be
within days for those in whom repeated attempts at tachy-
cardia induction during isoproterenol administration is un-
successful, and in whom the tachycardia was easily induced
prior to ablation. For those in whom such provocative
testing is not performed, waiting two to four weeks seems
advisable.
It may be difficult for team physicians and consultants
from the local community to make objective decisions to
restrict or proscribe sports for a competitive athlete. Bor-
derline cases can be reviewed by non-biased experts for the
purpose of helping make these decisions. Whether that
approach can be practically implemented has not been
determined. Alternatively, it has also been suggested that in
such borderline cases, both appropriate emergency equip-
ment and medical professionals versed in the operation of
that equipment be present at all practices and games.
However, there is considerable concern with regard to this
practice because its safety and efficacy have not been
established. Indeed, the practical implementation and reli-
ability of this approach to reverse potentially lethal arrhyth-
mias in out-of-hospital settings for the competing athlete is
highly questionable.
SYNCOPE
Unexplained syncope in an athlete is a potentially important
symptom that mandates a thorough evaluation. It may be
due to a variety of causes, including cardiovascular disease;
alternatively, it may not be associated with either structural
heart disease or a primary electrical disorder but rather to
mechanisms such as vasovagal syncope, which is a common
finding in highly trained athletes. Although vasovagal syn-
cope may be compatible with continued participation in all
competitive sports, caution should be used in making this
diagnosis in highly trained athletes without first definitively
excluding underlying structural cardiovascular disease. A
cardiac arrhythmia should be considered, particularly when
syncope occurs during or immediately after exercise.
A cause of syncope can be established in approximately
50% of patients. Often, a careful history and physical
examination will identify the etiology (7). When such an
evaluation does not determine the cause, further testing in
search of an arrhythmia is indicated. Ambulatory ECG
recordings are often unrevealing but nevertheless probably
worthwhile to obtain during the initial evaluation. Event or
loop recorders or implantable devices can be used to increase
the ECG sampling time. Tilt-table testing has been used to
assess patients at risk for vasovagal syncope, but the lack of
specificity of this test (particularly in endurance-trained
athletes in whom false-positive results can occur) requires a
particularly cautious interpretation of the results. Exercise
testing is useful and is optimally performed while recording
the ECG during the athletic activity in which the person
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participates. Provocative catecholamine stress testing with
either epinephrine, procainamide, or isoproterenol may be
useful to unmask cases of concealed LQTS, Brugada syn-
drome (BrS), or catecholaminergic polymorphic ventricular
tachycardia (CPVT) (8). Invasive electrophysiologic testing
is most likely to identify an arrhythmia responsible for
syncope in those patients with structural heart disease or an
abnormal ECG but can be considered in other athletes
when no other cause of the syncope has been identified,
remembering that the diagnostic yield of invasive electro-
physiologic testing is low in the absence of structural heart
disease.
TYPES OF ARRHYTHMIAS
Disturbances of sinus node function. Sinus tachycardia
and sinus bradycardia appropriate for the clinical situation
are not considered abnormal, and no tests are necessary.
Sinus arrhythmia and wandering pacemaker are generally
considered normal, and no tests are necessary unless the
arrhythmias result in inappropriately slow rates accompa-
nied by symptoms. Sinus arrhythmia and sinus bradycardia
are particularly common in the trained athlete.
Asymptomatic sinus pause or sinus arrest (less than 3 s) is
probably of no significance. Longer symptomatic pauses,
sinoatrial exit block, and sick sinus syndrome are considered
abnormal, and athletes should have a 12-lead, 24-h ECG,
and an exercise test. Mutations involving the cardiac sodium
channel encoded by SCN5A has been demonstrated in some
patients with progressive cardiac conduction disease and
congenital sick sinus syndrome (9,10). In an occasional
athlete experiencing syncope or near syncope, an electro-
physiologic study may be indicated and reveal abnormal
sinus node function, but in general, invasive electrophysi-
ologic testing is not helpful. Echocardiography should be
performed to exclude structural heart disease; other tests to
evaluate ventricular or valvular function may be indicated.
Recommendations:
1. Athletes with a normal or structurally abnormal heart
in whom the bradycardic rate is increased appropri-
ately by physical activity can participate in all com-
petitive sports consistent with the limitations im-
posed by the structural heart disease. They should be
reassessed periodically to determine that training
does not aggravate the bradycardia.
2. Athletes with syncope or near syncope should not
participate in sports where the likelihood of even a
momentary loss of consciousness may be hazardous
until the cause has been determined and treated, if
necessary.
3. Athletes with symptoms such as impaired conscious-
ness and fatigue clearly attributed to the arrhythmias
should be treated and if asymptomatic for two to three
months during treatment, they can participate in all
competitive sports after physician re-evaluation.
4. Athletes with symptomatic tachycardia/bradycardia
syndrome or inappropriate sinus tachycardia should
be treated. If no structural heart disease and asymp-
tomatic for two to three months, they can participate
in all competitive sports.
5. Athletes with pacemakers should not engage in
sports with a danger of bodily collision because such
trauma may damage the pacemaker system. This
restriction should clearly exclude activities where
direct blows to the chest are a part of the sport, such
as football, rugby, boxing, martial arts, hockey, and
lacrosse. Protective padding for the device is advis-
able for other sports such as soccer, basketball,
baseball, and softball where trauma is possible but
less likely.
Premature atrial complexes. In the absence of evidence of
structural heart disease and in the absence of symptoms
other than occasional palpitation, no evaluation other than
a 12-lead ECG is necessary.
Recommendation:
1. Athletes can participate in all competitive sports.
Atrial flutter (in the absence of WPW syndrome). In the
absence of an acute, limiting illness, sustained atrial flutter is
an uncommon rhythm disturbance in athletes without
structural heart disease. Therefore, an echocardiogram
should be performed to evaluate cardiovascular structure and
function. Because the potential for very rapid ventricular
rates exists if the atrial flutter conducts 1:1 to the ventricles,
ECG determination of the ventricular response during an
exercise test or athletic event during treatment is essential.
For some patients with paroxysmal atrial flutter, induction
of the arrhythmia by electrical stimulation may be consid-
ered before the exercise test, recognizing the difficult logis-
tics in doing this. A 12-lead ECG and, at times, long-term
24-h ECG may be necessary. Asymptomatic athletes who
have transient episodes of atrial flutter lasting less than 10 s
that do not increase in duration during exercise can partic-
ipate in all sports.
Recommendations:
1. Athletes with atrial flutter in the absence of structural
heart disease who maintain a ventricular rate that
increases and slows appropriately comparable to that
of a normal sinus response in relation to the level of
activity, while receiving no therapy or therapy with
AV nodal blocking drugs, can participate in class IA
competitive sports with the warning that rapid 1:1
conduction still may occur. However, full participa-
tion in all competitive sports should not be allowed
unless the athlete has been without atrial flutter for
two to three months with or without drug treatment.
Note that the use of beta-blockers is prohibited in
some competitive sports (see Introduction).
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2. Athletes with structural heart disease who have atrial
flutter can participate in class IA competitive sports
only after two to four weeks have elapsed without an
episode of atrial flutter.
3. Athletes without structural heart disease who have
elimination of the atrial flutter by an ablation tech-
nique or surgery can participate in all competitive
sports after two to four weeks without a recurrence,
or in several days after an electrophysiologic study
showing non-inducibility of the atrial flutter in the
presence of bi-directional isthmus block.
4. Athletes in whom anticoagulation is deemed neces-
sary cannot participate in competitive sports where
the danger of bodily collision is present.
Atrial fibrillation (in the absence of WPW syndrome). At-
rial fibrillation is far more common than atrial flutter and
may be present intermittently or chronically (11,12). Eval-
uation should include a search for the cause, such as
thyrotoxicosis. More often atrial fibrillation occurs in asso-
ciation with diseases such as CAD or hypertension. Evalu-
ation includes determination of the ventricular response
during athletic activity or an exercise test comparable to the
intended athletic competition. For some patients with
paroxysmal atrial fibrillation, electrical induction of atrial
fibrillation before the exercise test may be necessary, recog-
nizing the difficult logistics in doing this. A 12-lead ECG is
necessary, and long-term 24-h ECG recordings and an
echocardiogram are helpful in establishing the presence of
structural heart disease. Asymptomatic athletes who have
episodes of atrial fibrillation of 5 to 15 s that do not increase
in duration during exercise can participate in all sports.
Recommendations:
1. Athletes with asymptomatic atrial fibrillation in the
absence of structural heart disease who maintain a
ventricular rate that increases and slows appropri-
ately and is comparable to that of a normal sinus
response in relation to the level of activity, while
receiving no therapy or therapy with AV nodal-
blocking drugs, can participate in all competitive
sports. Note that the use of beta-blockers is prohib-
ited in some competitive sports.
2. Athletes who have atrial fibrillation in the presence
of structural heart disease who maintain a ventricular
rate comparable to that of an appropriate sinus
tachycardia during physical activity while receiving
no therapy or therapy with AV nodal-blocking drugs
can participate in sports consistent with the limita-
tions of the structural heart disease.
3. Athletes who require anticoagulation should not
participate in sports with danger of bodily collision
(13).
4. Athletes without structural heart disease who have
elimination of atrial fibrillation by an ablation tech-
nique, including surgery, may participate in all com-
petitive sports after four to six weeks without a
recurrence or after an electrophysiologic study has
confirmed non-inducibility.
Sinus node re-entry, inappropriate sinus tachycardia, and
atrial tachycardia (in the absence of WPW syndrome).
Sinus node re-entry, inappropriate sinus tachycardia, and
atrial tachycardia should be evaluated as described for atrial
flutter. Asymptomatic athletes who have episodes of tachy-
cardia of 5 to 10 s that do not increase in duration during
exercise can participate in all sports.
Recommendations:
1. Athletes with sinus node re-entry, inappropriate si-
nus tachycardia, or atrial tachycardia in the absence
of structural heart disease who maintain a ventricular
rate that increases and slows appropriately and is
comparable to that of a normal sinus response in
relation to the level of activity, with or without
therapy, can participate in all competitive sports.
2. Athletes with underlying structural heart disease can
participate only in competitive sports consistent with
the limitations of the heart disease.
3. Athletes without structural heart disease who have
elimination of the atrial tachyarrhythmia by an ablation
technique, including surgery, may participate in all
competitive sports after two to four weeks without a
recurrence or in several days after an electrophysiologic
study showing non-inducibility.
AV junctional escape beats/rhythm. Atrioventricular
junctional escape beats and junctional rhythm are common
in athletes. The clinical approach and final recommenda-
tions are the same as those given earlier for symptomatic
athletes with disturbances of sinus node function.
Premature AV junctional complexes. If the athlete is
asymptomatic except for occasional episodes of palpitations
that do not suggest a sustained tachycardia, evaluation need
include only a 12-lead ECG. In some athletes, a 24-h ECG
recording (during athletic activity if possible), echocardio-
gram, and an exercise test may be indicated.
Recommendations:
1. Athletes with a structurally normal heart and a
normal heart rate response to activity without evi-
dence of a sustained tachycardia can participate in all
competitive sports.
2. Athletes with an abnormal heart, depending on the
type and extent of the heart disease, can participate in
competitive sports consistent with the limitations of
the structural cardiac disease.
Non-paroxysmal AV junctional tachycardia. A form of
junctional tachycardia, so-called junctional ectopic tachycar-
dia, can be found in a permanent form in infants less than
six months old, whereas a transient form occurs mostly in
children but occasionally in adults (13). Most adults have a
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slower form of non-paroxysmal junctional tachycardia.
Evaluation generally includes a 12-lead ECG, echocardio-
gram, exercise test, and 24-h ECG recording during activ-
ity. Invasive studies may be necessary for some symptomatic
patients or for those with very rapid ventricular rates.
Recommendations:
1. Athletes without structural heart disease or symp-
toms who have a controlled ventricular rate that
increases and slows appropriately and is comparable
to that of a normal sinus response in relation to the
level of activity, with or without therapy, can partic-
ipate in all sports.
2. Athletes who have no symptoms but who have struc-
tural heart disease or incompletely controlled ven-
tricular rates can engage in class IA competitive
sports depending on the nature and extent of the
structural heart disease and the ventricular rate.
3. Athletes with inappropriately rapid ventricular rates,
with or without structural heart disease, should be
considered for treatment to control the ventricular
rate before participating in any sports. Athletes
whose tachycardia is controlled by therapy and veri-
fied by appropriate testing can participate in all
competitive sports consistent with their cardiac
status.
Supraventricular tachycardia. Atrioventricular nodal re-
entrant tachycardia and AV re-entry over a concealed
accessory pathway (with only retrograde conduction) (4,14)
are included in this category. If the diagnosis of the
supraventricular tachycardia cannot be made with certainty,
and if other clinical therapeutic circumstances warrant it,
invasive electrophysiologic studies might be indicated. It is
important to identify the rate response of the supraventric-
ular tachycardia during exercise. If the exercise does not
induce the tachycardia, attempts to induce the supraventric-
ular tachycardia (possibly with atrial or esophageal pacing)
may be useful, followed once again by an exercise test
performed by the athlete when the supraventricular tachy-
cardia has been initiated. The logistics to accomplish this
may be difficult. Asymptomatic athletes who have episodes
of supraventricular tachycardia of 5 to 10 s that do not
increase in duration during exercise can participate in all
sports.
Recommendations:
1. Athletes without structural heart disease who are
asymptomatic and have reproducible exercise-
induced supraventricular tachycardia prevented by
therapy and verified by appropriate testing can par-
ticipate in all competitive sports.
2. Athletes who do not have exercise-induced supraven-
tricular tachycardia but experience sporadic recur-
rences should be treated. However, because of the
unpredictable nature of the tachycardia, end points
for adequate therapy may be difficult to achieve; but
once established, these athletes can participate in all
activities consistent with their cardiac status. Asymp-
tomatic athletes who have episodes of supraventric-
ular tachycardia of 5 to 15 s that do not increase in
duration during exercise can participate in all sports
consistent with their cardiac status.
3. Athletes with syncope, near-syncope, or significant
symptoms secondary to arrhythmia or who have
significant structural heart disease in addition to the
arrhythmia should not participate in any competitive
sports until they have been adequately treated and
have no recurrence for two to four weeks (4). At that
time they can participate in class IA competitive
sports.
4. For those athletes with no structural heart disease
who have had successful catheter or surgical ablation,
are asymptomatic, and have no inducible arrhythmia
on follow-up electrophysiologic testing, all competi-
tive sports are permitted in several days. If no
electrophysiologic testing is done, full participation
is permitted if no spontaneous recurrence of tachy-
cardia for two to four weeks after ablation.
Ventricular pre-excitation (WPW syndrome). Required
noninvasive tests include a 12-lead ECG, exercise test, and
echocardiogram to exclude associated cardiovascular abnor-
malities. In some instances, a 24-h ECG recording during
athletic activity may be indicated. Electrophysiologic studies
are indicated in athletes with symptoms of impaired con-
sciousness, long-lasting palpitations, or rapid rates in whom
an ablation procedure is indicated.
In asymptomatic athletes with no history of palpitations
or tachycardia and no evidence of structural cardiac abnor-
malities, further evaluation may not be necessary. However,
the optimal management for these athletes is uncertain, and
continues to be debated (15,16). Furthermore, the younger
the patient, the less time the patient has had to develop
symptoms, and so the distinction between symptomatic and
asymptomatic WPW syndrome may be less meaningful in
the pediatric population. Sudden death in athletes with
pre-excitation is rare, and it appears to be confined largely to
those with accessory pathways that have short refractory
periods. Therefore, it may be advisable in selected asymp-
tomatic athletes who anticipate moderate or high level
activity to undergo electrophysiology study to determine the
anterograde refractory period of the accessory pathway, the
minimum RR interval between pre-excited complexes in
atrial fibrillation, and the number of accessory pathways.
Individuals with multiple accessory pathways or ventricular
rates exceeding 240 beats/min should be offered catheter
ablation of the accessory pathway (17,18). For those athletes
with a history of palpitations, syncope, or near syncope, it is
mandatory to assess the functional capabilities and electro-
physiologic properties of the accessory pathway.
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Recommendations:
1. Athletes without structural heart disease, without a
history of palpitations, or without tachycardia (par-
ticularly those 20 to 25 years old or more) can
participate in all competitive sports. However, in
younger age groups, a more in-depth evaluation
including an electrophysiologic study may be recom-
mended before allowing participation in moderate-
to high-intensity competitive sports.
2. Athletes with episodes of AV reciprocating tachycar-
dia should be treated as previously recommended (see
section on Supraventricular Tachycardia). However,
it should be appreciated that they can develop atrial
fibrillation with rapid ventricular rates. Electrical
induction of atrial fibrillation to determine the short-
est QRS interval between two complexes conducted
over the accessory pathway during isoproterenol ad-
ministration or exercise is recommended. Those ath-
letes in whom the shortest cycle length is less than
250 ms should undergo ablation of the accessory
pathway.
3. Athletes with episodes of atrial flutter/fibrillation
and syncope or near syncope whose maximal ventric-
ular rate at rest (without therapy) as a result of
conduction over the accessory pathway exceeding 240
beats/min should be considered for catheter ablation
therapy of the accessory pathway prior to continuing
competition. Those whose ventricular rate during
isoproterenol administration is less than 240 beats/
min and who have no episodes of syncope or near
syncope appear to be at low risk for sudden cardiac
death.
4. Athletes with no structural heart disease who have
had successful catheter or surgical ablation of the
accessory pathway, are asymptomatic, and have nor-
mal AV conduction and no inducible arrhythmia by
follow-up electrophysiologic study can participate in
all competitive sports in several days. Those without
an electrophysiologic study and no spontaneous re-
currence of tachycardia for two to four weeks after
ablation can participate in all competitive sports.
Premature ventricular complexes. Noninvasive tests rec-
ommended include a 12-lead ECG and exercise test. If
there is evidence to suggest the presence of structural heart
disease, an echocardiogram is indicated, and a 24-h ECG
recording may be beneficial. Even without evidence of
structural heart disease, if an increase in the number of
premature ventricular complexes or complex ventricular
arrhythmias occurs during exercise (with or without treat-
ment, or substantial reduction or abolition following a
period of deconditioning), further evaluation may be indi-
cated. In some of these athletes thought to have a structur-
ally normal heart, cardiac catheterization and angiography
may reveal otherwise undetected abnormalities, including
occult CAD, congenital coronary anomalies, ARVC, car-
diac tumor, or evidence of cardiomyopathy. The more
recently recognized channelopathy known as CPVT should
be considered (see the following text).
Frequent and complex ventricular tachyarrhythmias are
common in trained athletes; they are usually unassociated
with underlying cardiovascular abnormalities and do not
appear to convey increased risk (18). Deconditioning usually
results in loss or diminution of these arrhythmias, providing
evidence of their benign clinical nature (19).
Recommendations:
1. Athletes without structural heart disease who have
premature ventricular complexes at rest and during
exercise, and exercise testing (comparable to the sport
in which they compete) can participate in all com-
petitive sports. Should the premature ventricular
complexes increase in frequency during exercise or
exercise testing to the extent that they produce
symptoms of impaired consciousness, significant fa-
tigue, or dyspnea, the athlete can participate in class
IA competitive sports only.
2. Athletes with structural heart disease who are in
high-risk groups and have premature ventricular
complexes (with or without treatment) can partici-
pate in class IA competitive sports only. Such ath-
letes with premature ventricular complexes that are
suppressed by drug therapy (as assessed by ambula-
tory ECG recordings) during participation in the
sport can compete in only class IA competitive
sports.
Ventricular tachycardia (VT). Nonsustained or sustained
monomorphic or polymorphic VT is always a potentially
serious occurrence. Noninvasive tests to be performed in-
clude a 12-lead ECG, exercise test, and echocardiography.
In some patients, 24-h ECG recording during exercise may
be indicated. Echocardiography, cardiac catheterization,
and electrophysiologic study should be considered to verify
that the heart is structurally normal and to establish the
mechanism or location, or both, of the VT. A possible
exception is the patient with accelerated idioventricular
rhythm, in which the ventricular rate is similar to the sinus
rate. In such patients, if they have no significant structural
heart disease, the approach should be similar to that in
individuals with premature ventricular complexes.
Recommendations:
1. Athletes with a structurally normal heart and mono-
morphic nonsustained or sustained VT that can be
localized to a specific site(s) in the heart are candi-
dates for a catheter ablation procedure that may
potentially offer a cure. Following such a successful
ablation procedure, with subsequent failure to induce
VT during electrophysiologic study (EPS) with/with-
out isoproterenol when the VT was reproducibly
induced before ablation, the athlete can resume full
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competitive activity within two to four weeks. A more
conservative approach is recommended for the ath-
lete who chooses drug suppression because cat-
echolamines released during athletic activity can
counter the suppressive effects of the drug, and the
VT can re-emerge. In that situation, generally the
athlete should not compete in any sports for at least
two to three months after the last VT episode. If
there have been no clinical recurrences, and the VT is
not inducible by exercise/exercise testing or EPS, and
the athlete has no structural heart disease, all com-
petitive sports may be permitted. Because decondi-
tioning can result in the loss or lessening of ventricular
arrhythmias (19), a short period of deconditioning and
retesting can be considered in some athletes.
2. For the athlete with structural heart disease and VT,
moderate- and high-intensity competition is contra-
indicated regardless of whether the VT is suppressed
or ablated. Only class IA competitive sports are
permitted.
3. An exception to this general recommendation is the
asymptomatic athlete with brief (generally less than 8
to 10 consecutive ventricular beats) episodes of non-
sustained monomorphic VT, rates generally less than
150 beats/min, and no structural heart disease estab-
lished by noninvasive and invasive tests. These ath-
letes do not appear to be at increased risk for sudden
cardiac death. If exercise testing (preferably by am-
bulatory ECG recording during the specific compet-
itive activity) demonstrates suppression of the VT or
no significant worsening compared with baseline,
participation in all competitive sports is permissible.
4. The desire of the athlete to continue athletic com-
petition should not represent the primary indication
for use of an implantable cardioverter-defibrillator
(ICD). The efficacy with which these devices will
terminate a potentially lethal arrhythmia under the
extreme conditions of competitive sports, with the
associated metabolic and autonomic changes, and
possible myocardial ischemia, is unknown. In addi-
tion, sports with physical contact may result in
damage to the ICD and/or lead, preventing normal
function. For athletes with ICDs, all moderate and
high intensity sports are contraindicated. Class IA
sports are permitted.
Ventricular flutter and ventricular fibrillation.
Recommendation:
1. Athletes with conditions that result in cardiac arrest
in the presence or absence of structural heart disease
generally are treated with an ICD and cannot partic-
ipate in any moderate- or high-intensity competitive
sports. However, athletes with ICDs and who have
had no episodes of ventricular flutter or ventricular
fibrillation requiring device therapy for six months
may engage in class IA competitive sports. Recom-
mendations in the section on VT also apply.
First-degree AV block. In asymptomatic athletes with
structurally normal hearts, if the QRS complex is normal,
no further evaluation other than a 12-lead ECG is neces-
sary. If the QRS complex is abnormal, or the PR interval is
excessively prolonged (0.3 s or more), an exercise stress test,
24-h ECG recording and echocardiogram may be indicated.
Possibly an EPS might be necessary to determine the site
and duration of conduction delay.
Recommendation:
1. Asymptomatic athletes without evidence of structural
heart disease, in whom the first-degree AV block does
not worsen with exercise, can participate in all com-
petitive sports. If underlying heart disease is present,
its nature and severity can independently dictate
alternative restrictions.
Type 1 second-degree (Wenckebach) AV block. Wenck-
ebach AV nodal block can be present in otherwise normal,
well-trained endurance athletes (4). Recommended evalua-
tions include a 12-lead ECG, exercise test, and echocardio-
gram. A 24-h ECG recording during athletic activity may
be indicated in some athletes. In those athletes with type 1
second-degree AV block and co-existing bundle-branch
block, EPS may be indicated to identify the presence of
His-Purkinje Wenckebach block.
Recommendations:
1. Asymptomatic athletes with a structurally normal
heart and no worsening or actual improvement of AV
block with exercise or recovery can participate in all
competitive sports.
2. Asymptomatic athletes with a structurally abnormal
heart in whom AV block disappears or does not
worsen with exercise or recovery can participate in all
competitive sports, as determined by the limitations
of the cardiac abnormality.
3. Asymptomatic athletes in whom type 1 second-
degree AV block initially appears or worsens with
exercise or during the recovery period should be
evaluated further (e.g., for possible intra- or infra-
His block) and may require pacemaker therapy. Such
athletes can participate in class IA competitive
sports.
4. Athletes treated with pacemakers should not engage
in competitive sports with a danger of bodily collision
because such trauma may damage the pacemaker
system.
Type 2 second-degree (Mobitz) AV block. The evolution
and treatment of this abnormality is considered to be the
same as in acquired complete heart block. It should be
treated with permanent pacing before any athletic activity.
Athletes with pacemakers should not participate in compet-
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itive sports that pose a danger of bodily collision because
such trauma may damage the pacemaker system. Before
allowing athletes to engage in these activities, an exercise
test should be done at the level of activity demanded by the
particular sport to be certain that the paced heart rate
increases appropriately.
Congenital complete heart block. The clinical approach
to evaluating the severity of the cardiovascular abnormality
includes an echocardiogram, 12-lead ECG, 24-h ECG
recording during exercise, and exercise stress test (exercise
testing should be performed at the same exercise level as
that during the sports activity).
Recommendations:
1. Athletes with a structurally normal heart and normal
cardiac function, with no history of syncope or near
syncope, a narrow QRS complex, ventricular rates at
rest greater than 40 to 50 beats/min increasing ap-
propriately with exertion, no or only occasional pre-
mature ventricular complexes, and no VT during
exertion can participate in all competitive sports.
2. Athletes with ventricular arrhythmia, symptoms of
fatigue, near-syncope, or syncope should have a
pacemaker implanted before they participate in com-
petitive sports. Athletes with pacemakers should not
participate in competitive sports when the danger of
bodily collision exists because such trauma may dam-
age the pacemaker system. Before allowing athletes
to engage in these activities, an exercise test should
be conducted at the level of activity demanded by the
particular sport so as to be certain that the paced
heart rate increases appropriately.
3. Athletes with abnormal hemodynamic status, as
those with an intracardiac shunt, cannot participate
in any competitive sports without a pacemaker. Re-
strictions are the same as those in recommendation 2.
Acquired complete heart block.
Recommendations:
1. Patients with acquired complete heart block should
be treated with pacing before any athletic activity.
2. Athletes with a pacemaker should not participate in
competitive sports posing a danger of bodily collision
because such trauma may damage the pacemaker
system.
Complete right bundle-branch block. Evaluation in-
cludes a 12-lead ECG, exercise test, and echocardiogram. In
some instances, a 24 h ECG recording may be indicated.
Recommendation:
1. Athletes without ventricular arrhythmias who do not
develop AV block with exercise and who have no
symptoms can participate in all competitive sports
consistent with their cardiac status. This also applies
to athletes with associated left-axis deviation.
Complete left bundle-branch block. Evaluation includes
a 12-lead ECG, exercise test, and echocardiogram. In some
instances, a 24-h ECG recording may be indicated. Because
of the rarity of acquired left bundle-branch block in children
and its association with syncope from presumed paroxysmal
AV block, an invasive EPS should be considered in young
patients.
Recommendations:
1. Adult athletes with acquired left bundle-branch
block should follow the recommendations under the
section entitled Complete Right Bundle-Branch
Block.
2. Athletes with a normal HV interval and a normal AV
conduction response to pacing can participate in
all competitive sports consistent with their cardiac
status.
3. Athletes with abnormal AV conduction characterized
by an HV interval greater than 90 ms or a His-
Purkinje block should have pacemaker implantation.
They should be restricted from competitive sports
that hold a danger of bodily collision because such
trauma may damage the pacemaker system.
Inherited arrhythmia syndromes. LONG QT SYNDROME.
The definitive clinical diagnosis of congenital long QT
syndrome (LQTS) can be complex (20). Debate continues
as to what QTc constitutes the upper limit of normal. An
increasing proportion of asymptomatic individuals with
genetically proven LQTS are found to have a normal resting
ECG with a heart rate corrected QT interval (QTc) by
Bazett’s formula of less than 460 ms (genotype positive/
phenotype negative LQTS). In addition, a QTc of 440 ms,
used in the past as an upper limit of normal, is present in far
too many normal individuals (greater than 25%) to serve as
a meaningful upper limit cut-off value. In general, a QTc of
470 ms or more in males and 480 ms or more in females
requires further investigation as to the presence of congen-
ital (or acquired) causes of QT prolongation. A patient with
LQTS and a resting QTc of 500 ms or more is generally
considered at increased clinical risk for a significant arrhyth-
mia (21). One approach to the diagnosis of congenital
LQTS is to utilize the “Priori-Schwartz” score that incor-
porates QTc, T-wave morphology, symptomatic presenta-
tion, and family history into the diagnostic algorithm (21).
A “Priori-Schwartz” score of 4 or more suggests high
clinical probability for LQTS. In addition, genetic testing
for the five cardiac ion-channel genes responsible for 75% of
LQTS (LQT1, LQT2, LQT3, LQT5, and LQT6) is now
available as a commercial diagnostic test (22).
Mutations involving the structural protein ankyrin-B
underlie the rare LQT4 form (23). Mutations involving the
KCNJ2-encoded IK1 potassium channel account for ap-
proximately one-half of Andersen-Tawil syndrome (ATS1)
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characterized by abnormal U waves, a prolonged QU
interval, periodic paralysis, and facial and skeletal dysmor-
phisms. The ATS1 has been annotated in the past as
LQT7.
Physical exertion (particularly swimming) appears to be a
common trigger for ventricular arrhythmias in LQT1,
whereas individuals with LQT2 seem more at-risk to
auditory/emotional triggers, and patients with LQT3 may
be at greater risk during rest and inactivity (24,25). How-
ever, exceptions to these genotype-phenotype correlations
hinder genotype-specific tailoring of competitive sports
recommendations. The entire personal and family pheno-
type must be incorporated before any eligibility or disqual-
ification decision is rendered.
Recommendations:
1. Regardless of QTc or underlying genotype, all com-
petitive sports, except those in class IA category
should be restricted in a patient who has previously
experienced either: 1) an out-of-hospital cardiac ar-
rest, or 2) a suspected LQTS-precipitated syncopal
episode.
2. Asymptomatic patients with baseline QT prolonga-
tion (QTc of 470 ms or more in males, 480 ms or
more in females) should be restricted to class IA
sports. The restriction limiting participation to class
IA activities may be liberalized for the asymptomatic
patient with genetically proven type 3 LQTS
(LQT3).
3. Patients with genotype-positive/phenotype-negative
LQTS (i.e., identification of a LQTS-associated mu-
tation in an asymptomatic individual with a nondiag-
nostic QTc) may be allowed to participate in competi-
tive sports. Although the risk of sudden cardiac death is
not zero in such individuals, there is no compelling data
available to justify precluding these individuals (who are
being identified with increasing frequency) from com-
petitive activities. Because of the strong association
between swimming and LQT1, persons with genotype-
positive/phenotype-negative LQT1 should refrain from
competitive swimming.
4. LQTS patients with an ICD/pacemaker should not
engage in sports with a danger of bodily collision
because such trauma may damage the pacemaker
system. The presence of an ICD should restrict
individuals to class IA activities.
SHORT QT SYNDROME. Individuals with the short QT
syndrome (SQTS) (QTc less than 300 ms) have a short QT
interval and ventricular refractory period, and at least some
of them have “gain-of-function” abnormalities in either IKr
(KCNH2) or IKs (KCNQ1) (26).
Recommendation:
1. Until the phenotype of SQTS is better understood, a
universal restriction from competitive sports with the
possible exception of class IA activities seems to
represent the most prudent recommendation (27).
CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR
TACHYCARDIA (CPVT). Approximately one-half of patients
with CPVT is pursuant to mutations involving the RyR2-
encoded ryanodine receptor (sarcoplasmic reticulum cal-
cium release channel). Such individuals are vulnerable to
exercise-induced VT/ventricular fibrillation.
Recommendations:
1. Symptomatic patients have a poor prognosis unless
treated with an implantable cardioverter-defibrillator
(ICD) (28) and all such patients are restricted from
competitive sports with the possible exception of min-
imal contact, class IA activities. As with LQT1, pa-
tients with CPVT should be restricted from competitive
swimming. Asymptomatic patients detected as part of
familial screening with documented exercise- or
isoproterenol-induced VT should refrain from all com-
petitive sports except possible class IA activities. A less
restrictive approach may be possible for the genotype-
positive/phenotype-negative (asymptomatic, no induc-
ible VT) athlete.
BRUGADA SYNDROME (BrS). Brugada syndrome (29), char-
acterized by an accentuated J-wave primarily in leads V1
through V3, with ST-segment elevation, often followed by
a negative T-wave and an R prime, may be the cause of
sudden unexplained death syndrome, typically during sleep.
Only 15% to 20% of BrS is established as a channelopathy
due to mutations involving the SCN5A-encoded alpha
subunit of the cardiac sodium channel (30). Individuals with
BrS and no previous cardiac arrests may have a high risk of
sudden death if they have inducibility of ventricular arrhyth-
mias and a previous history of syncope (28). Hyperthermia
can potentially unmask the Brugada ECG pattern in pa-
tients with BrS, who can then display fever-induced poly-
morphic VT. Death often occurs with mild activity or
during sleep.
Recommendations:
1. Although a clear association between exercise and
sudden death has not been established, and because
of the potential impact of hyperthermia, restriction to
participation in class IA sports seems advisable.
2. The presence of an ICD device warrants the same
restrictions to class IA sports as previously outlined.
doi:10.1016/j.jacc.2005.02.014
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